1. |
Tilg H, Adolph TE, Gerner RR, et al. The intestinal microbiota in colorectal cancer. Cancer Cell, 2018, 33(6): 954-964.
|
2. |
Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol, 2015, 33(16): 1797-1808.
|
3. |
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet, 2014, 383(9927): 1490-1502.
|
4. |
Kirstein MM, Lange A, Prenzler A, et al. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist, 2014, 19(11): 1156-1168.
|
5. |
Aoyagi K, Kouhuji K, Kizaki J, et al. Molecular targeting to treat gastric cancer. World J Gastroenterol, 2014, 20(38): 13741-13755.
|
6. |
Poulin EJ, Haigis KM. No back seat for a progression event-K-RAS as a therapeutic target in CRC. Genes Dev, 2017, 31(4): 333-335.
|
7. |
van Leuken RJ, Luna-Vargas MP, Sixma TK, et al. Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle, 2008, 7(17): 2710-2719.
|
8. |
Makarova OV, Makarov EM, Lührmann R. The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J, 2001, 20(10): 2553-2563.
|
9. |
Gan Z, Han K, Lin S, et al. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. Biol Res, 2017, 50(1): 15.
|
10. |
Huang Y, Pan XW, Li L, et al. Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation. Oncotarget, 2016, 7(16): 22016-22030.
|
11. |
Liu S, Liu X, Wang H, et al. Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells. Oncol Rep, 2015, 33(5): 2477-2483.
|
12. |
Yuan X, Sun X, Shi X, et al. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo. Oncol Rep, 2015, 34(2): 823-832.
|
13. |
An Y, Yang S, Guo K, et al. Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro. World J Surg Oncol, 2015, 13(1): 255.
|
14. |
许良中, 杨文涛. 免疫组织化学反映结果的判断标准. 中国癌症杂志, 1996, 6(4): 229-231.
|
15. |
Sun W, Yao L, Jiang B, et al. Spindle and kinetochore-associated protein 1 is overexpressed in gastric cancer and modulates cell growth. Mol Cell Biochem, 2014, 391(1-2): 167-174.
|
16. |
Mamlouk S, Childs LH, Aust D, et al. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nat Commun, 2017, 8: 14093.
|
17. |
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol, 2016, 17(6): 738-746.
|
18. |
Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family proteins in cancer. Pharmacol Ther, 2017, 173: 58-66.
|
19. |
Wan L, Yu W, Shen E, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut, 2017, [Epub ahead of print].
|
20. |
Allgayer H, Fulda S. An introduction to molecular targeted therapy of cancer. Adv Med Sci, 2008, 53(2): 130-138.
|
21. |
Shih YH, Luo TY, Chiang PF, et al. EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer. J Control Release, 2017, 258: 196-207.
|
22. |
Augustine TA, Baig M, Sood A, et al. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer, 2015, 112(2): 313-318.
|
23. |
Fraile JM, Quesada V, Rodríguez D, et al. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene, 2012, 31(19): 2373-2388.
|
24. |
Lygerou Z, Christophides G, Séraphin B. A novel genetic screen for snRNP assembly factors in yeast identifies a conserved protein, Sad1p, also required for pre-mRNA splicing. Mol Cell Biol, 1999, 19(3): 2008-2020.
|
25. |
Dong X, Su H, Jiang F, et al. miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer. Oncol Lett, 2018, 15(6): 8311-8318.
|
26. |
Xu Y, Zhu MR, Zhang JY, et al. Knockdown of ubiquitin-specific peptidase 39 inhibits the malignant progression of human renal cell carcinoma. Mol Med Rep, 2018, 17(3): 4729-4735.
|
27. |
Yuan X, Sun X, Shi X, et al. USP39 regulates the growth of SMMC-7721 cells via FoxM1. Exp Ther Med, 2017, 13(4): 1506-1513.
|